BUND FINANCE › Stocks › TEVA
Teva Pharmaceutical Industries Limited (TEVA)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +4.47% above its 50-day average.
- It is +20.04% above its 200-day average (long-term uptrend).
- It sits at 89% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$15.9B | US$14.9B | US$15.8B | US$16.5B | US$17.3B |
| Net income | US$417.0M | −US$2.4B | −US$559.0M | −US$1.6B | US$1.4B |
| EPS (diluted) | 0.38 | -2.20 | -0.50 | -1.45 | 1.20 |
| Gross margin | 47.8% | 46.7% | 48.3% | 48.7% | 51.8% |
| Operating margin | 10.8% | -14.7% | 2.7% | -1.8% | 12.5% |
| Net margin | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
| Free cash flow | US$236.0M | US$1.0B | US$842.0M | US$749.0M | US$1.1B |
| Total debt | US$23.5B | US$21.6B | US$20.2B | US$18.1B | US$17.4B |
| Cash | US$2.2B | US$2.8B | US$3.2B | US$3.3B | US$3.6B |
Compound annual growth: revenue 2.1% · net income 35.6% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 98.2x | 23.2x | 27.1x |
| EV / EBITDA | 30.6x | 12.5x | 16.5x |
| Operating margin | 10.5% | — | 3.6% |
| Net margin | 2.9% | — | -0.0% |
| Debt / equity | 4.02 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic …
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice